$14.49
+0.00 (+0.00%)
Last updated: Jul 15, 2026 06:00
Fundamentals Overview
Amicus Therapeutics, Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Risk (Beta)
0.48 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
Sentiment weakening (6 downgrades) · 3M vs S&P 500: -9.4% · 3M vs Healthcare sector: -6.8%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Recent institutional grades: majority downgrades. Current institutional positions: Buy: 8, Equal Weight: 1, Hold: 4, Market Perform: 1, Neutral: 4, Overweight: 12.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-29.29; current price is $14.49. That’s a -302.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 16.33 |
| P/S (TTM) | 7.17 |
| P/FCF (TTM) | 152.43 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.84 |
| Quick Ratio (TTM) | 1.88 |
| Cash Ratio (TTM) | 0.9 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -4.27% |
| Gross margin (TTM) | 87.91% |
| Operating margin (TTM) | 5.17% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for FOLD.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Jefferies | downgrade | Buy | Hold | 2026-01-22 |
| Leerink Partners | downgrade | Outperform | Market Perform | 2025-12-29 |
| Citigroup | downgrade | Buy | Neutral | 2025-12-22 |
| Needham | downgrade | Buy | Hold | 2025-12-19 |
| Cantor Fitzgerald | downgrade | Overweight | Neutral | 2025-12-19 |
| JP Morgan | maintain | Overweight | Overweight | 2025-11-06 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-11-05 |
| Needham | upgrade | Hold | Buy | 2025-09-18 |
| Morgan Stanley | upgrade | Equal Weight | Overweight | 2025-07-17 |
| UBS | maintain | Buy | Buy | 2025-05-02 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-05-02 |
| Needham | maintain | Hold | Hold | 2025-02-20 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-02-20 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2025-01-15 |
| Needham | maintain | Hold | Hold | 2025-01-13 |
| Morgan Stanley | downgrade | Overweight | Equal Weight | 2024-12-13 |
| JP Morgan | maintain | Overweight | Overweight | 2024-11-12 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-11-07 |
| Guggenheim | maintain | Buy | Buy | 2024-11-07 |
| UBS | maintain | Buy | Buy | 2024-11-07 |
| B of A Securities | maintain | Buy | Buy | 2024-10-17 |
| Morgan Stanley | maintain | Overweight | Overweight | 2024-10-11 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-09-20 |
| JP Morgan | maintain | Overweight | Overweight | 2024-08-16 |
| Guggenheim | upgrade | Neutral | Buy | 2024-05-14 |
| Morgan Stanley | maintain | Overweight | Overweight | 2024-05-10 |
| UBS | maintain | Buy | Buy | 2024-05-10 |
| B of A Securities | maintain | Buy | Buy | 2024-05-10 |
| JP Morgan | maintain | Overweight | Overweight | 2024-03-18 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-02-29 |